SCHEMBL14548463

SCHEMBL14548463

CCCCOc1ccc2c(c1)CCC(C(=O)OCC)C2=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRA P10827 2/20 0.55
▸ THRB P10828 2/20 0.55
▸ ALDH1A1 P00352 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ GAA P10253 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ BRD4 O60885 1/20 0.48
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ PPARD Q03181 6/20 0.44
▸ PPARA Q07869 1/20 0.40
▸ CYP24A1 Q07973 3/20 0.40
▸ CYP26A1 O43174 2/20 0.40
▸ CYP27A1 Q02318 1/20 0.40
▸ MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9233039 0.95 THRA (0.50) THRATHRBALDH1A1MEN1GAA
SCHEMBL9235535 0.92 MAPT (0.52) THRATHRBALDH1A1MEN1GAA
SCHEMBL7290713 0.87 CYP24A1 (0.53) ALDH1A1MEN1GAAMAPTKMT2A
SCHEMBL972021 0.87 CYP24A1 (0.53) ALDH1A1MEN1GAAMAPTKMT2A
SCHEMBL9233137 0.85 MAPT (0.50) THRATHRBALDH1A1MEN1GAA
SCHEMBL5665208 0.84 MAOB (0.52) ALDH1A1MEN1GAAMAPTKMT2A
SCHEMBL20572886 0.83 MAOB (0.54) ALDH1A1MEN1GAAMAPTKMT2A
SCHEMBL9621126 0.83 THRA (0.54) THRATHRBALDH1A1MEN1GAA
SCHEMBL8050780 0.82 MEN1 (0.55) ALDH1A1MEN1GAAMAPTKMT2A
SCHEMBL2064320 0.81 MEN1 (0.53) ALDH1A1MEN1GAAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED (IN) 2007-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them GPR119, NR1H3, NR1H2 THRA 1445/4885THRB 628/4885ALDH1A1 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback